These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18480167)

  • 21. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction.
    de Waal R; Cohen K; Maartens G
    PLoS One; 2013; 8(5):e63623. PubMed ID: 23723990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
    Viganò A; Brambilla P; Cafarelli L; Giacomet V; Borgonovo S; Zamproni I; Zuccotti G; Mora S
    Antivir Ther; 2007; 12(3):297-302. PubMed ID: 17591019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stavudine in antiretroviral therapy: is this the end?
    Brinkman K
    AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
    [No Abstract]   [Full Text] [Related]  

  • 24. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
    Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
    J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
    Nolan D; John M; Mallal S
    Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
    Jemsek JG; Arathoon E; Arlotti M; Perez C; Sosa N; Pokrovskiy V; Thiry A; Soccodato M; Noor MA; Giordano M
    Clin Infect Dis; 2006 Jan; 42(2):273-80. PubMed ID: 16355341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142.
    Hulgan T; Haubrich R; Riddler SA; Tebas P; Ritchie MD; McComsey GA; Haas DW; Canter JA
    AIDS; 2011 Jan; 25(1):37-47. PubMed ID: 20871389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo.
    Lagathu C; Kim M; Maachi M; Vigouroux C; Cervera P; Capeau J; Caron M; Bastard JP
    Biochimie; 2005 Jan; 87(1):65-71. PubMed ID: 15733739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
    Brinkman K; Smeitink JA; Romijn JA; Reiss P
    Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of switching to protease inhibitor monotherapy on nucleoside analogue-related adverse events.
    Clumeck N; Hill A; Moecklinghoff C
    AIDS Rev; 2014; 16(4):236-45. PubMed ID: 25350532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does atazanavir cause lipodystrophy?
    Gazzard BG; Moyle G
    J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-associated lipodystrophy: impact of antiretroviral therapy.
    Guaraldi G; Stentarelli C; Zona S; Santoro A
    Drugs; 2013 Sep; 73(13):1431-50. PubMed ID: 24002702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.
    Bucher HC; Young J; Battegay M
    J Antimicrob Chemother; 2004 Aug; 54(2):303-5. PubMed ID: 15269200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face.
    Kadouch JA; van Rozelaar L; Karim RB; Hoekzema R
    Int J STD AIDS; 2013 Sep; 24(9):685-94. PubMed ID: 23970569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
    Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
    HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
    Hansen AB; Obel N; Nielsen H; Pedersen C; Gerstoft J
    HIV Med; 2011 Mar; 12(3):157-65. PubMed ID: 20722752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.